Peter C Enzinger

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Impact of hospital volume on recurrence and survival after surgery for gastric cancer
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Surg 245:426-34. 2007
  2. ncbi request reprint A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Dig Dis Sci 50:2218-23. 2005
  3. pmc Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer
    P C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 20:475-80. 2009
  4. ncbi request reprint Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:1892-7. 2006
  5. ncbi request reprint CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Virchows Arch 450:529-37. 2007
  6. ncbi request reprint Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:4787-92. 2007
  7. ncbi request reprint Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:208-13. 2006
  8. pmc Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 27:5506-12. 2009
  9. ncbi request reprint A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Institute, Boston, Massachusetts, USA
    Dig Dis Sci 51:1033-8. 2006
  10. ncbi request reprint Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Brigham Women s Hospital, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:59-65. 2006

Detail Information

Publications37

  1. pmc Impact of hospital volume on recurrence and survival after surgery for gastric cancer
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Surg 245:426-34. 2007
    ..However, because such data may be significantly influenced by the impact of postoperative mortality, and may be imbalanced for factors important to survival, the true nature of this relationship remains uncertain...
  2. ncbi request reprint A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Dig Dis Sci 50:2218-23. 2005
    ..When used as a single-agent, a tri-weekly schedule may be preferable for this patient population...
  3. pmc Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer
    P C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 20:475-80. 2009
    ..Recent studies have examined the addition of docetaxel to fluorouracil and cisplatin in advanced esophagogastric cancer...
  4. ncbi request reprint Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:1892-7. 2006
    ..To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer...
  5. ncbi request reprint CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Virchows Arch 450:529-37. 2007
    ..Additional studies are necessary to examine the role of DNA methylation in treatment efficacy...
  6. ncbi request reprint Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:4787-92. 2007
    ..We evaluated an oral regimen of capecitabine and erlotinib in patients with advanced pancreatic cancer who had experienced treatment failure with standard first-line therapy with gemcitabine...
  7. ncbi request reprint Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:208-13. 2006
    ....
  8. pmc Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 27:5506-12. 2009
    ..We explored the efficacy and toxicity of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in a multi-institutional, randomized, phase II study...
  9. ncbi request reprint A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Institute, Boston, Massachusetts, USA
    Dig Dis Sci 51:1033-8. 2006
    ..4 months. We conclude that while the combination of irinotecan and cisplatin may have activity in aggressive neuroendocrine tumor subtypes, this combination is inactive in patients with well-differentiated neuroendocrine tumors...
  10. ncbi request reprint Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Brigham Women s Hospital, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:59-65. 2006
    ..Whether these results apply to other cancer types is unknown but worthy of further study...
  11. ncbi request reprint A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Invest 24:229-34. 2006
    ..The use of doxorubicin as an alternative to epirubicin in the ECF regimen has not been evaluated...
  12. ncbi request reprint Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Cancer 110:581-9. 2007
    ..A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC...
  13. ncbi request reprint Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 60:661-70. 2007
    ....
  14. pmc Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 7:e38231. 2012
    ..To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer...
  15. pmc A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
    Jason E Faris
    Department of Medical Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USA
    Invest New Drugs 30:1614-20. 2012
    ..MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin-β family. We conducted an open-label Phase II study with MKC-1 in patients with advanced pancreatic cancer...
  16. doi request reprint Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 30:2963-8. 2012
    ..We performed a phase II study to evaluate the efficacy of temozolomide in combination with bevacizumab in patients with locally advanced or metastatic NETs...
  17. ncbi request reprint Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 24:1898-903. 2006
    ....
  18. doi request reprint Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Lancet Oncol 11:48-54. 2010
    ....
  19. pmc O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:338-45. 2009
    ..We evaluated the prevalence of MGMT deficiency in neuroendocrine tumors and correlated MGMT deficiency with treatment response to temozolomide-based regimens...
  20. ncbi request reprint Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:401-6. 2006
    ..We evaluated the efficacy of an oral regimen of temozolomide and thalidomide in patients with metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors...
  21. pmc Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 18:377-8. 2013
    ..We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor)...
  22. ncbi request reprint Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
    Andrew X Zhu
    Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 59:285-93. 2007
    ....
  23. ncbi request reprint A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Invest 24:346-50. 2006
    ..9 months and the median overall survival time was 7.8 months. We conclude that vinorelbine has minimal toxicity but only minor antitumor activity in patients with advanced gastroesophageal adenocarcinoma...
  24. pmc Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer
    Michael S Lee
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Oncologist 18:281-7. 2013
    ..To determine the efficacy and toxicity of weekly neoadjuvant cetuximab combined with irinotecan, cisplatin, and radiation therapy in patients with locally advanced esophageal or gastroesophageal junction cancer...
  25. ncbi request reprint A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer
    David P Ryan
    Dana Farber Partners Cancer Care Gastrointestinal Cancer Center, Brigham and Women s Hospital, Dana Farber Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer Invest 21:505-11. 2003
    ....
  26. ncbi request reprint Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3555-61. 2006
    ..We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors...
  27. pmc Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:193-8. 2009
    ..We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line therapy with gemcitabine...
  28. ncbi request reprint Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 11:6650-6. 2005
    ..Abnormalities of EGFR and related pathways may have an effect on responsiveness of advanced colorectal cancer to combination chemotherapy with gefitinib...
  29. ncbi request reprint Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
    David P Ryan
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer 107:2482-9. 2006
    ..The effect of gemcitabine on proteasome inhibition by bortezomib in whole blood was also investigated...
  30. ncbi request reprint Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:8453-60. 2005
    ..Although several comprehensive dietary questionnaires have been validated and calibrated in healthy populations, similar studies have not been performed among cancer patients...
  31. pmc Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study
    Andrew X Zhu
    Division of Hematology Oncology, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 27:3027-35. 2009
    ..To assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response...
  32. ncbi request reprint A Phase II trial of gemcitabine for metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer 101:934-9. 2004
    ..Gemcitabine is generally well tolerated and possesses demonstrated activity against a wide range of malignancies. The authors assessed the efficacy of gemcitabine in the treatment of patients with metastatic neuroendocrine tumors...
  33. ncbi request reprint Gastrointestinal cancer in older patients
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Semin Oncol 31:206-19. 2004
    ..There is a paucity of information concerning the treatment of elderly patients with other gastrointestinal malignancies...
  34. ncbi request reprint Esophageal cancer
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 349:2241-52. 2003
  35. pmc Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis
    Austin M Dulak
    Departments of Medical Oncology, Cancer Biology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer Res 72:4383-93. 2012
    ..Together, our results defined genomic features that were common and distinct to various gut-derived adenocarcinomas, potentially informing novel opportunities for targeted therapeutic interventions...
  36. ncbi request reprint The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer
    A David McCollum
    Texas Oncology, PA, and Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Am J Clin Oncol 29:40-4. 2006
    ..We conducted a multicenter, phase II study to examine the combination of capecitabine and thalidomide (Cape/Thal) in patients with refractory metastatic CRC...
  37. ncbi request reprint Should people with Barrett's esophagus, who are at risk for cancer of the esophagus, avoid alcohol?
    Peter C Enzinger
    Health News 10:16. 2004